Antibody-drug conjugate · Cytotoxic, directed at nectin-4 · developed by Innate Pharma
IPH4502 is an antibody-drug conjugate in which a humanized IgG1 antibody binds nectin-4 on tumor cells and delivers the topoisomerase I inhibitor exatecan through a cleavable linker. After internalization, released exatecan inhibits DNA replication and induces tumor cell apoptosis, with a bystander effect on neighboring cells. It is being studied in advanced or metastatic solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06781983 | Phase 1 | Advanced or Metastatic Solid Tumors | Active not recruiting | IPHA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced or Metastatic Solid Tumors
Updated Oct 18, 2026. Something wrong or missing? Report it on the IPHA page.
See IPHA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IPHA catalysts and pipeline →